Navigation Links
Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
Date:5/17/2011

GREENWOOD VILLAGE, Colo., May 17, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE)("Ampio" or the "Company"), a clinical stage developer of new uses for previously approved drugs and new molecular entities ("NMEs"), announces that its common stock has been approved for listing on the NASDAQ Capital Market.  The shares are scheduled to trade under the ticker symbol "AMPE" and the Company understands that trading will commence on that market in the coming days.

"The Company is pleased to make the transition to NASDAQ and raise our profile in the investment community," commented Don Wingerter, Ampio's chief executive officer. "We believe being listed on the Nasdaq Capital Market will provide Ampio with greater visibility, additional liquidity for our common stock, and opportunities to expand our investor base." Pending the listing change, Ampio's common stock will continue to trade on the OTC Bulletin Board.  

About Ampio

The company is currently performing a phase II clinical trial for the treatment diabetic macular edema and is evaluating the data from a recently completed phase III clinical trial for the treatment of premature ejaculation. Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statem
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 ... of Glenmark Pharmaceuticals Limited India (GPL), announces the ... a novel clinical development candidate, GBR 1302, a ... developed by the Glenmark Biologics Research Centre located ... GBR 1302 is based on Glenmark,s innovative BEAT ...
(Date:8/19/2014)... Tenn. , Aug. 19, 2014   ... provide its patient experience technology to ... Under the five-year agreement, CarePoint Health will deploy ... Bayonne Medical Center, Christ Hospital and Hoboken University ... offers a range of software solutions to help ...
(Date:8/19/2014)... 19, 2014 Talyst, a market leader in ... the 2014 NPPA Summer Conference in Las ... its 340B software products and services.   ... supplying over 400 customers with a variety of software ... including its latest solution, AutoSplit® Contract Pharmacy and 340B ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Talyst Exhibits at the NPPA Summer Conference 2
... Development of New Vaccines to Prevent Tuberculosis , ... ROCKVILLE, Md. , July 1 ... E. Connolly has been named President and Chief Executive Officer.  He ... Executive Vice President and General Manager of Wyeth Vaccines.  He will take ...
... , July 1 The refinements in ... the fifth generation Leksell Gamma Knife® Perfexion™ are radically ... and other brain disorders. With Perfexion, physicians are applying ... treating more non-malignant targets located in critical areas and ...
Cached Medicine Technology:Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 2Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 3Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 4Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 2Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 3Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 4Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 5
(Date:8/20/2014)... researchers have discovered that the immune system is defective in ... reason why sufferers have ongoing issues with pain. , The ... could also help to explain why some painkillers may ... (IBS) affects up to 10% of the community. There ... unexplained gut pain, which often has the greatest impact on ...
(Date:8/20/2014)... Barbara Bronson Gray ... -- Although it,s extremely rare, colds, flu and other ... elevated risk for stroke in children, a new study suggests. ... a stroke in the United States, said Dr. Heather Fullerton, ... and pediatrics at the University of California, San Francisco Benioff ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The Board ... Perkins Eastman is pleased to announce the ... services in China and the surrounding region. ... Richard Sprow AIA has relocated to the ... career in healthcare planning and design and to better ...
(Date:8/20/2014)... August 20, 2014 With 3943.8% growth, Connexion ... of the nation’s fastest growing companies. The Inc. 500 ranks ... care sector. Connexion Point is the #1 fastest growing company ... Medicare and Medicaid, and its clients include four of the ... employs 1,000 people and has offices and contact centers in ...
(Date:8/20/2014)... that the amygdala stimulates stress responses in adults, ... University have found that the amygdala has an ... development of nonhuman primates. , The results are ... . , The amygdala is a region of ... to threatening situations and learning about threats. Alterations ...
Breaking Medicine News(10 mins):Health News:Pain treatments less effective for those with irritable bowel 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... who feel powerful are more likely to believe they ... according to new study in the Journal of ... anthropomorphism, or the tendency to attribute humanlike characteristics, intentions, ... important downstream consequences of anthropomorphism that go beyond simple ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- Women who ... to give birth to a single healthy baby following the ... to have two embryos implanted at the same time, an ... from an analysis of data involving nearly 1,400 women who ...
... News) -- How people fare when oral cancer recurs depends ... has found. The research included 77 people in Australia ... in the thin, flat cells that line the lips and ... However, the cancer came back, and they all subsequently had ...
... --- Busy doctors can miss important details about a ... Northwestern Medicine researchers have created a whip-smart assistant for ... that alerts doctors during an exam when a patient,s ... software program significantly improved primary care physicians, performance and ...
... are offered fewer and less effective choices ... deaths, according to a new UCSF study. The ... prostate cancer often are under-treated through hormone therapy or ... such as surgery and radiation therapies. Instead, say the ...
... HealthDay Reporter , TUESDAY, Dec. 21 (HealthDay News) -- The ... to play in helping people who have trouble connecting to ... a small group of healthy people, investigators found that the ... of friendliness, playfulness and love, and induced a lowering of ...
Cached Medicine News:Health News:Why do risks with human characteristics make powerful consumers feel lucky? 2Health News:Single Embryo Beat Double Embryo Transfer in IVF Study 2Health News:Single Embryo Beat Double Embryo Transfer in IVF Study 3Health News:Recurrence of Oral Cancer Found to Signal Poor Outcome 2Health News:Smarter systems help busy doctors remember 2Health News:Smarter systems help busy doctors remember 3Health News:Age plays too big a role in prostate cancer treatment decisions 2Health News:Age plays too big a role in prostate cancer treatment decisions 3Health News:Does 'Club Drug' Ecstasy Have Therapeutic Value? 2Health News:Does 'Club Drug' Ecstasy Have Therapeutic Value? 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: